IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['io-108']
immune-onc therapeutics to present encouraging phase 1 data for io-108 at aacr annual meeting 2023 - 
Research Intelligence, PharmaDJ, focus on China pharma & biotech industry and investment